Patients may experience nausea, vomiting, diarrhea, constipation, stomach pain, reduced appetite, fatigue, or other concerns
Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, et al
Choosing between tirzepatide and semaglutide depends on your goals, tolerability, and coverage landscape
Aykan DA, Kesim M, Ayan B, Kurt A (2019) Anti-inflammatory and antinociceptive activities of glucagon-like peptides: evaluation of their actions on serotonergic, nitrergic, and opioidergic systems
GLP-1 agonists and GIP antagonists GIP antagonism is also a potential obesity treatment as in preclinical studies improved the metabolic profile and reduced food intake [54,55,56]
The 2024 Standards of Care in Diabetes does emphasize use of certain GLP-1 medications over others for certain goals